Tidligere leder av Utprøvingsenheten, Steinar Aamdal, går til Ultimovacs

Vår porteføljebedrift Ultimovacs AS har nylig ansatt professor…
March 6, 2018/by Elisabeth K. Andersen

Photocure: FDA approval for new indications

Photocure´s drug and device for detection of bladder cancer may also be used in the ongoing surveillance of afflicted patients. 
February 16, 2018/by Elisabeth K. Andersen

– Productive year for Targovax

Overall, the prospects are great for 2018, says Øystein Soug in a press release from Targovax.
February 15, 2018/by Elisabeth K. Andersen

Prestigious BIA-funding to OncoImmunity and Oncoinvent

Two of our portfolio companies receive funding in though competition.
February 5, 2018/by Elisabeth K. Andersen

Oncoinvent with new production facility at Nydalen

Our portfolio company Oncoinvent opened brand-new lab and production…
December 20, 2017/by Elisabeth K. Andersen

PCI Biotech with pivotal study in 2018

Our portfolio company PCI Biotech (OSE: PCIB) got an early Christmas…
December 20, 2017/by Elisabeth K. Andersen
Nordicna Novector

ASH: Betalutin® shows strong clinical profile

Our portfolio company Nordic Nanovector ASA  presented updated…
December 11, 2017/by Elisabeth K. Andersen

Nordic Nanovector ASA – Results for the Third Quarter 2017

Nordic Nanovector is ready to initiate the pivotal Phase 2b study,…
November 22, 2017/by Elisabeth K. Andersen
Nordicna Novector

41 MNOK til tre prosjekter innen legemiddelproduksjon

I følge Dagens Medisin får tre prosjekter innen legemiddelproduksjon…
November 15, 2017/by Elisabeth K. Andersen

Photocure with excellent Q3 results

Our portfolio company Photocure ASA is on the roll in the U.S…
November 14, 2017/by Elisabeth K. Andersen

Improved reimbursement for Photocure in the U.S.

Our portfolio company Photocure with more positive news from…
November 7, 2017/by Elisabeth K. Andersen

Targovax with encouraging third quarter

Our portfolio company Targovax presented third quarter results…
November 7, 2017/by Elisabeth K. Andersen